Airway gene therapy and cystic fibrosis
DW Parsons,
DW Parsons
Department of Pulmonary Medicine, Women's and Children's Hospital, and Department of Paediatrics, University of Adelaide, North Adelaide, South Australia
Search for more papers by this authorDW Parsons,
DW Parsons
Department of Pulmonary Medicine, Women's and Children's Hospital, and Department of Paediatrics, University of Adelaide, North Adelaide, South Australia
Search for more papers by this author Dr David W Parsons, Department of Pulmonary Medicine, Women's and Children's Hospital, and Department of Paediatrics, University of Adelaide, North Adelaide, South Australia, 5006, Australia. Fax: +61 8 8161 7050; email: [email protected]
Abstract
Abstract: Airway disease in cystic fibrosis (CF) is the major cause of death and is presently inadequately treatable, but genetic therapies offer the hope that such life-long disease will be curable, or at least satisfactorily treated. Normal pathogen defences that have evolved on airway surfaces also prevent the various gene vectors now available from producing effective gene transfer. Nevertheless, findings from basic research and human clinical trials are revealing how these barriers might be overcome or circumvented, with benefits to therapeutic efficacy and patient safety. Though progress is slower than expected or desired, the therapeutic rewards will be great when safe and effective gene therapy for CF airway disease becomes a clinical reality.
REFERENCES
- 1 Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066–73.
- 2 Crystal RG, McElvaney NG, Rosenfeld MA et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 1994; 8: 42–51.
- 3 Boucher RC, Knowles MR, Johnson LG et al. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. Hum. Gene Ther. 1994; 5: 615–39.
- 4 Hyde SC, Gill DR, Higgins CF et al. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 1993; 362: 250–5.DOI: 10.1038/362250a0
- 5 Alton EW, Middleton PG, Caplen NJ et al. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat. Genet. 1993; 5: 135–42.DOI: 10.1038/ng1093-135
- 6 Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 2002; 109: 571–7.DOI: 10.1172/JCI200215217
- 7 Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv. Drug Deliv. Rev. 2002; 54: 1359–71.
- 8 Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv. Drug Deliv. Rev. 2002; 54: 1373–93.DOI: 10.1016/S0169-409X(02)00145-X
- 9 Driskell RA, Engelhardt JF. Current status of gene therapy for inherited lung diseases. Annu. Rev. Physiol. 2003; 65: 585–612.DOI: 10.1146/annurev.physiol.65.092101.142426
- 10 Pickles RJ, Fahrner JA, Petrella JM, Boucher RC, Bergelson JM. Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J. Virol. 2000; 74: 6050–7.DOI: 10.1128/JVI.74.13.6050-6057.2000
- 11 Wang G, Williams G, Xia H et al. Apical barriers to airway epithelial cell gene transfer with amphotropic retroviral vectors. Gene Ther. 2002; 9: 922–31.DOI: 10.1038/sj.gt.3301714
- 12 Joseph PM, O'Sullivan BP, Lapey A et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum. Gene Ther. 2001; 12: 1369–82.DOI: 10.1089/104303401750298535
- 13 Ferrari S, Griesenbach U, Geddes DM, Alton E. Immunological hurdles to lung gene therapy. Clin. Exp. Immunol. 2003; 132: 1–8.DOI: 10.1046/j.1365-2249.2003.02124.x
- 14 Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 2001; 19: 225–30.DOI: 10.1038/85664
- 15 Sinn PL, Hickey MA, Staber PD et al. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J. Virol. 2003; 77: 5902–10.DOI: 10.1128/JVI.77.10.5902-5910.2003
- 16 Wang G, Sinn PL, McCray PB Jr. Development of retroviral vectors for gene transfer to airway epithelia. Curr. Opin. Mol. Ther. 2000; 2: 497–506.
- 17 Medina MF, Kobinger GP, Rux J et al. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol. Ther. 2003; 8: 777–89.DOI: 10.1016/j.ymthe.2003.07.003
- 18 Borthwick DW, Shahbazian M, Krantz QT, Dorin JR, Randell SH. Evidence for stem-cell niches in the tracheal epithelium. Am. J. Respir. Cell Mol. Biol. 2001; 24: 662–70.
- 19 Limberis M, Anson DS, Fuller M, Parsons DW. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum. Gene Ther. 2002; 13: 1961–70.DOI: 10.1089/10430340260355365
- 20 Lim FY, Kobinger GP, Weiner DJ, Radu A, Wilson JM, Crombleholme TM. Human fetal trachea-SCID mouse xenografts: efficacy of vesicular stomatitis virus-G pseudotyped lentiviral-mediated gene transfer. J. Pediatr. Surg. 2003; 38: 834–9.DOI: 10.1016/S0022-3468(03)00106-4
- 21 Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J. Virol. 2003; 77: 3495–504.DOI: 10.1128/JVI.77.6.3495-3504.2003
- 22 Wagner JA, Nepomuceno IB, Messner AH et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 2002; 13: 1349–59.DOI: 10.1089/104303402760128577
- 23 Flotte TR, Zeitlin PL, Reynolds TC et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum. Gene Ther. 2003; 14: 1079–88.DOI: 10.1089/104303403322124792
- 24 Moss R. Aerosol transgene delivery to the respiratory tract: the tgAAVCF experience. American Society of Gene Therapy, 6th Annual Meeting. Washington , DC , USA : 2003.
- 25 Friedmann T. Gene therapy's new era: a balance of unequivocal benefit and unequivocal harm. Mol. Ther. 2003; 8: 5–7.DOI: 10.1016/S1525-0016(03)00190-4
- 26 Ratjen F, Doring G. Cystic fibrosis. Lancet 2003; 361: 681–9.DOI: 10.1016/S0140-6736(03)12567-6
- 27 Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na(+) absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 2004; 10: 487–93.DOI: 10.1038/nm1028
- 28 Engelhardt JF, Yankaskas JR, Ernst SA et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat. Genet. 1992; 2: 240–8.DOI: 10.1038/ng1192-240
- 29 Yonemitsu Y, Kitson C, Ferrari S et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat. Biotechnol. 2000; 18: 970–3.DOI: 10.1038/79463
Citing Literature
